Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis

Publisher： Karger

E-ISSN： 1421-9875|33|2|118-124

ISSN： 0257-2753

Source： Digestive Diseases, Vol.33, Iss.2, 2015-0, pp. : 118-124

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Medical Treatment of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis

By  

Digestion, Vol. 64, Iss. 3, 2001-12 ,pp. : 137-150

Karger

Access to resources Recommend Favorite

Primary sclerosing cholangitis: a review and update on therapeutic developments

By Tabibian James H   Lindor Keith D  

Expert Review of Gastroenterology and Hepatology, Vol. 7, Iss. 2, 2013-02 ,pp. : 103-114

Informa Healthcare

Access to resources Recommend Favorite

Primary Sclerosing Cholangitis: Diagnostic and Therapeutic Problems

By  

Digestive Diseases, Vol. 29, Iss. 1, 2011-11 ,pp. : 41-45

Karger

Access to resources Recommend Favorite

Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis

By  

Digestive Diseases, Vol. 35, Iss. 3, 2017-03 ,pp. : 267-274

Karger

Access to resources Recommend Favorite

Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis

By  

Digestive Diseases, Vol. 33, Iss. 2, 2015-0 ,pp. : 115-117

Karger

Access to resources Recommend Favorite